Browse the evidence

Chronic stimulation of pancreatic beta-cells by incretin agonists may lead to beta-cell exhaustion, receptor downregulation, and potentially beta-cell failure over the long term.

While generally safe, long-term use of incretin medications may theoretically stress pancreatic beta-cells. Doctors monitor for this, but the long-term human data is still being gathered. It is important to discuss any concerns about long-term safety with your healthcare provider.

Modern obesogenic environments (sedentary lifestyle, high-calorie processed food) exploit evolutionary adaptations (brain expansion, efficient fat storage) leading to a 'normalization' of obesity phenotypes and genotypes.

Your environment is shaping your biology. To combat obesity, you must actively create a 'non-obesogenic' environment (healthy food access, physical activity) because your evolutionary biology is wired to store fat in such settings.

Chronic GIPR agonism may lead to desensitization that mimics functional antagonism, potentially explaining why both agonists and antagonists result in weight loss.

There is a theoretical possibility that long-term use of GIP-activating drugs could lead to receptor desensitization, acting like a blocker. However, current clinical evidence does not strongly support this in the brain, and these drugs remain effective for weight loss. Monitor your progress with your doctor.

Unimolecular tetra-receptor agonists (TC4) simultaneously activate GLP-1R, GIPR, GcgR, and Y2R, resulting in superior metabolic efficacy (weight loss and glycemic control) compared to mono- or dual-agonists by leveraging synergistic receptor engagement.

This research describes a new class of peptide drugs that target four metabolic receptors (GLP-1, GIP, Glucagon, and PYY) simultaneously. In preclinical studies, this approach showed strong potential for treating obesity and type 2 diabetes with fewer side effects like nausea than older drugs. It is not yet available for human use.

Tirzepatide administration is associated with novel postmarketing adverse events including palpitations, musculoskeletal pain, and headaches, which were not prominent in initial clinical trials.

If you experience palpitations, muscle pain, or headaches after starting Tirzepatide, report these to your doctor. These are not the typical stomach issues and may require dose adjustment or injection site changes.

South Asian ethnicity is predisposed to 'thin-fat' obesity (normal weight obesity), leading to higher risks of diabetes, hypertension, and dyslipidemia at lower BMIs.

If you are South Asian, your risk for diabetes and heart disease starts at a lower weight than other ethnicities. Even if your BMI is normal, you might have 'thin-fat' obesity. Get regular check-ups for blood sugar, blood pressure, and cholesterol, and focus on building muscle and staying active.

Tirzepatide, a dual GLP-1/GIP receptor agonist, may modify the natural course of lipedema by targeting its underlying immunometabolic, inflammatory, and fibrotic pathophysiology, rather than solely reducing body weight.

If you have lipedema, especially with insulin resistance, talk to your doctor about tirzepatide. It’s not just for weight loss; it may help reduce the inflammation and fibrosis causing your pain and stiffness. Since it’s a newer treatment for lipedema, ask about clinical trials or off-label use if appropriate for your case.

An automatic remote weight management system using smart scales and cloud-based dashboards can effectively monitor treatment response and identify early deviations from weight trajectories without increasing patient burden.

Using a smart scale that automatically uploads data to your doctor's dashboard can help catch weight regain early without you having to do extra work. This tool helps your care team prioritize who needs help, potentially keeping you on your medication and avoiding unnecessary visits.

GLP-1 RAs are associated with an increased risk of suicidal behavior and self-harm, particularly in patients with underlying mental health vulnerabilities or dysphoria.

If you are taking Semaglutide and experience mood changes, depression, or suicidal thoughts, contact your healthcare provider immediately. Do not ignore these symptoms. Regular screening for mental health is recommended for all patients on this medication.

Creatine supplementation trends toward increasing lean muscle mass in prostate cancer patients undergoing ADT.

Creatine supplementation may help preserve lean muscle mass in prostate cancer patients on hormone therapy, though the evidence is not yet definitive. It is worth discussing with your healthcare provider as a potential supportive measure.

Bariatric surgery (Roux-en-Y gastric bypass or sleeve gastrectomy) is technically feasible and safe for patients with pre-existing ileostomy or colostomy, without causing increased ostomy output or dehydration.

If you have an existing ostomy (ileostomy or colostomy) and are considering bariatric surgery, current preliminary evidence suggests it is feasible and safe, with no increased risk of dehydration or output changes compared to patients without an ostomy. Consult with a bariatric surgeon to evaluate your specific case, as individual factors like the cause of your ostomy and overall health status will determine your candidacy.

Incretin-based therapies may attenuate intestinal iron absorption, independent of reduced intake, potentially contributing to iron deficiency in susceptible individuals.

Monitor iron levels if you have a history of anemia or low iron, as semaglutide may slightly reduce absorption.

Heterozygous variants in the POMC gene (specifically p.Arg90His, p.Ser94Gly, p.Ser94=, and p.Ala195=) are associated with an intermediate obesity phenotype in adults, likely due to haploinsufficiency affecting melanocortin peptide processing.

If you carry a heterozygous POMC variant, you may have an intermediate form of genetic obesity that responds differently to standard interventions. This information can help tailor your treatment plan, though functional validation of specific variants is still needed.

Tirzepatide as an adjunct to insulin in adults with Type 1 Diabetes and overweight/obesity produces significant body weight reduction and reduced insulin requirements, but current evidence is insufficient to establish durable glycaemic benefit or long-term safety.

For adults with Type 1 Diabetes and obesity, Tirzepatide is a promising tool for significant weight loss and reducing insulin needs. However, it is not yet proven to reliably improve long-term blood sugar control or safety. If used, it requires careful monitoring for side effects like nausea and potential risks like DKA, especially if insulin is reduced too aggressively. It is currently an investigational option, not a standard of care.

BPC-157 accelerates tissue repair (tendons, muscles, ligaments, GI mucosa) by stimulating angiogenesis and modulating inflammation, though it lacks FDA approval and robust human clinical trials.

BPC-157 is a peptide studied for its ability to speed up the healing of tendons, muscles, and gut lining. While animal studies show promising results for tissue repair, it is not yet approved by the FDA for human use. It is sometimes used off-label in sports medicine, but robust human clinical trials are still needed to confirm its safety and efficacy.

Carnivore and animal-based diets do not consistently improve athletic performance and may impair high-intensity exercise capacity due to reduced muscle glycogen and constrained metabolic flexibility.

Do not switch to a carnivore or animal-based diet expecting better performance, especially if your sport involves sprinting, lifting, or high-intensity intervals. These diets reduce muscle glycogen and make it harder to produce energy quickly. While you might lose weight or feel less bloated, your high-intensity performance will likely suffer. Stick to established sports nutrition guidelines that prioritize carbohydrate availability for intense training.

Carnivore and animal-based diets pose significant risks for micronutrient deficiencies, altered gut microbiota, and unfavorable lipid profiles, with no long-term safety data in athletes.

Be cautious with long-term carnivore or animal-based diets. You risk missing key nutrients like fiber, vitamin C, and magnesium, which can affect gut health and recovery. Your cholesterol levels might also rise significantly. There is no long-term safety data for athletes on these diets. If you choose to try it, monitor your blood work closely and consider it experimental, not optimal.

Ramadan Fasting (RF) protocols (28-30 days) have insufficient evidence to draw definitive conclusions regarding their effects on body weight, composition, or glycemic control compared to Time-Restricted Feeding.

Do not rely on Ramadan Fasting as a proven, standalone strategy for weight loss or metabolic health improvement based on current scientific evidence. The data is too sparse to recommend it over established methods like TRF.

The renal safety of long-term low-carbohydrate diets in obese individuals remains undetermined due to insufficient reporting of renal function data in clinical trials.

Do not start a low-carb diet if you have existing kidney disease. For healthy obese individuals, current data does not show harm, but long-term safety is not proven because most studies don't track kidney function. Monitor your health with a doctor.

In specific preclinical models (OVX rats, T2D mice), high-dose GLP-1 agonists can improve bone mass and microarchitecture, but these effects require doses much higher than those approved for human obesity treatment.

Animal studies show GLP-1s *can* help bones, but only at doses far higher than what humans take. This suggests the drug itself isn't a 'bone builder' at standard doses, and the bone loss seen in humans is likely due to weight loss, not a direct toxic effect of the drug.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, can cause immediate, systemic IgE-mediated hypersensitivity reactions (including urticaria and pruritus) shortly after the initial dose.

If you are prescribed Tirzepatide, be aware that a small percentage of users (1-2%) may experience an allergic reaction, such as hives or itching, shortly after the injection. This can happen even if you tolerated other GLP-1 drugs like semaglutide. If you develop a rash, hives, or difficulty breathing within minutes to hours of your dose, seek medical attention immediately and discontinue the drug.

The optimal ratio of GLP-1 to glucagon/GIP agonism in combination therapies is unknown, and the balance between efficacy (liver fat reduction) and safety (hyperglycemia, side effects) remains a key challenge.

There is no single 'best' combination therapy yet. The field is still debating whether to maximize GLP-1, add glucagon, or add GIP. Current trials are testing different ratios (e.g., 1:1 vs 5:1 GLP-1:glucagon). Patients should expect that these therapies are evolving and that side effects (nausea, hyperglycemia) may limit the dose that can be tolerated.

GABA signaling can induce the transdifferentiation of alpha cells into beta-like cells, potentially reversing chemically induced diabetes in vivo.

There is experimental evidence that GABA, a neurotransmitter, might help convert alpha cells (which raise blood sugar) into beta-like cells (which lower blood sugar) in diabetic mice. However, the paper also notes that other studies found no such regeneration with long-term GABA or artesunate administration. This remains a research area, not a current treatment option for humans.

Liraglutide shows a statistically significant disproportionality signal for completed suicide, but this is likely due to statistical fragility, small case numbers, and notoriety bias rather than a true pharmacological effect.

While Liraglutide shows a statistical signal for completed suicide in reporting databases, this is based on a very small number of cases (14) and is likely influenced by reporting bias. It should not be interpreted as evidence of increased risk.